1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global HER2-Positive Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Grifola Frondosa 1.2.3 Surgery 1.2.4 Radiation and Chemotherapy 1.2.5 Endocrine Therapy 1.2.6 Molecular Targeted Therapy 1.3 Market by Application 1.3.1 Global HER2-Positive Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospital 1.3.3 Specialist Clinic 1.3.4 Biotechnology and Pharmaceutical Companies 1.3.5 Research and Academic Institutions 1.3.6 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global HER2-Positive Breast Cancer Market Perspective (2016-2027) 2.2 HER2-Positive Breast Cancer Growth Trends by Regions 2.2.1 HER2-Positive Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 HER2-Positive Breast Cancer Historic Market Share by Regions (2016-2021) 2.2.3 HER2-Positive Breast Cancer Forecasted Market Size by Regions (2022-2027) 2.3 HER2-Positive Breast Cancer Industry Dynamic 2.3.1 HER2-Positive Breast Cancer Market Trends 2.3.2 HER2-Positive Breast Cancer Market Drivers 2.3.3 HER2-Positive Breast Cancer Market Challenges 2.3.4 HER2-Positive Breast Cancer Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top HER2-Positive Breast Cancer Players by Revenue 3.1.1 Global Top HER2-Positive Breast Cancer Players by Revenue (2016-2021) 3.1.2 Global HER2-Positive Breast Cancer Revenue Market Share by Players (2016-2021) 3.2 Global HER2-Positive Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by HER2-Positive Breast Cancer Revenue 3.4 Global HER2-Positive Breast Cancer Market Concentration Ratio 3.4.1 Global HER2-Positive Breast Cancer Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by HER2-Positive Breast Cancer Revenue in 2020 3.5 HER2-Positive Breast Cancer Key Players Head office and Area Served 3.6 Key Players HER2-Positive Breast Cancer Product Solution and Service 3.7 Date of Enter into HER2-Positive Breast Cancer Market 3.8 Mergers & Acquisitions, Expansion Plans 4 HER2-Positive Breast Cancer Breakdown Data by Type 4.1 Global HER2-Positive Breast Cancer Historic Market Size by Type (2016-2021) 4.2 Global HER2-Positive Breast Cancer Forecasted Market Size by Type (2022-2027) 5 HER2-Positive Breast Cancer Breakdown Data by Application 5.1 Global HER2-Positive Breast Cancer Historic Market Size by Application (2016-2021) 5.2 Global HER2-Positive Breast Cancer Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America HER2-Positive Breast Cancer Market Size (2016-2027) 6.2 North America HER2-Positive Breast Cancer Market Size by Type 6.2.1 North America HER2-Positive Breast Cancer Market Size by Type (2016-2021) 6.2.2 North America HER2-Positive Breast Cancer Market Size by Type (2022-2027) 6.2.3 North America HER2-Positive Breast Cancer Market Size by Type (2016-2027) 6.3 North America HER2-Positive Breast Cancer Market Size by Application 6.3.1 North America HER2-Positive Breast Cancer Market Size by Application (2016-2021) 6.3.2 North America HER2-Positive Breast Cancer Market Size by Application (2022-2027) 6.3.3 North America HER2-Positive Breast Cancer Market Size by Application (2016-2027) 6.4 North America HER2-Positive Breast Cancer Market Size by Country 6.4.1 North America HER2-Positive Breast Cancer Market Size by Country (2016-2021) 6.4.2 North America HER2-Positive Breast Cancer Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe HER2-Positive Breast Cancer Market Size (2016-2027) 7.2 Europe HER2-Positive Breast Cancer Market Size by Type 7.2.1 Europe HER2-Positive Breast Cancer Market Size by Type (2016-2021) 7.2.2 Europe HER2-Positive Breast Cancer Market Size by Type (2022-2027) 7.2.3 Europe HER2-Positive Breast Cancer Market Size by Type (2016-2027) 7.3 Europe HER2-Positive Breast Cancer Market Size by Application 7.3.1 Europe HER2-Positive Breast Cancer Market Size by Application (2016-2021) 7.3.2 Europe HER2-Positive Breast Cancer Market Size by Application (2022-2027) 7.3.3 Europe HER2-Positive Breast Cancer Market Size by Application (2016-2027) 7.4 Europe HER2-Positive Breast Cancer Market Size by Country 7.4.1 Europe HER2-Positive Breast Cancer Market Size by Country (2016-2021) 7.4.2 Europe HER2-Positive Breast Cancer Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific HER2-Positive Breast Cancer Market Size (2016-2027) 8.2 Asia-Pacific HER2-Positive Breast Cancer Market Size by Type 8.2.1 Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2016-2021) 8.2.2 Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2022-2027) 8.2.3 Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2016-2027) 8.3 Asia-Pacific HER2-Positive Breast Cancer Market Size by Application 8.3.1 Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2016-2021) 8.3.2 Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2022-2027) 8.3.3 Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2016-2027) 8.4 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region 8.4.1 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2016-2021) 8.4.2 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America HER2-Positive Breast Cancer Market Size (2016-2027) 9.2 Latin America HER2-Positive Breast Cancer Market Size by Type 9.2.1 Latin America HER2-Positive Breast Cancer Market Size by Type (2016-2021) 9.2.2 Latin America HER2-Positive Breast Cancer Market Size by Type (2022-2027) 9.2.3 Latin America HER2-Positive Breast Cancer Market Size by Type (2016-2027) 9.3 Latin America HER2-Positive Breast Cancer Market Size by Application 9.3.1 Latin America HER2-Positive Breast Cancer Market Size by Application (2016-2021) 9.3.2 Latin America HER2-Positive Breast Cancer Market Size by Application (2022-2027) 9.3.3 Latin America HER2-Positive Breast Cancer Market Size by Application (2016-2027) 9.4 Latin America HER2-Positive Breast Cancer Market Size by Country 9.4.1 Latin America HER2-Positive Breast Cancer Market Size by Country (2016-2021) 9.4.2 Latin America HER2-Positive Breast Cancer Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa HER2-Positive Breast Cancer Market Size (2016-2027) 10.2 Middle East & Africa HER2-Positive Breast Cancer Market Size by Type 10.2.1 Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2016-2021) 10.2.2 Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2022-2027) 10.2.3 Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2016-2027) 10.3 Middle East & Africa HER2-Positive Breast Cancer Market Size by Application 10.3.1 Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2016-2021) 10.3.2 Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2022-2027) 10.3.3 Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2016-2027) 10.4 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country 10.4.1 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2016-2021) 10.4.2 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Pfizer (Pharmacia and Upjohn Company) 11.1.1 Pfizer (Pharmacia and Upjohn Company) Company Details 11.1.2 Pfizer (Pharmacia and Upjohn Company) Business Overview 11.1.3 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Introduction 11.1.4 Pfizer (Pharmacia and Upjohn Company) Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.1.5 Pfizer (Pharmacia and Upjohn Company) Recent Development 11.2 Novartis 11.2.1 Novartis Company Details 11.2.2 Novartis Business Overview 11.2.3 Novartis HER2-Positive Breast Cancer Introduction 11.2.4 Novartis Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.2.5 Novartis Recent Development 11.3 AstraZeneca Pharmaceuticals 11.3.1 AstraZeneca Pharmaceuticals Company Details 11.3.2 AstraZeneca Pharmaceuticals Business Overview 11.3.3 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Introduction 11.3.4 AstraZeneca Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.3.5 AstraZeneca Pharmaceuticals Recent Development 11.4 Eli Lilly 11.4.1 Eli Lilly Company Details 11.4.2 Eli Lilly Business Overview 11.4.3 Eli Lilly HER2-Positive Breast Cancer Introduction 11.4.4 Eli Lilly Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.4.5 Eli Lilly Recent Development 11.5 Roche Group 11.5.1 Roche Group Company Details 11.5.2 Roche Group Business Overview 11.5.3 Roche Group HER2-Positive Breast Cancer Introduction 11.5.4 Roche Group Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.5.5 Roche Group Recent Development 11.6 Merck 11.6.1 Merck Company Details 11.6.2 Merck Business Overview 11.6.3 Merck HER2-Positive Breast Cancer Introduction 11.6.4 Merck Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.6.5 Merck Recent Development 11.7 Jiangsu HengRui Medicine 11.7.1 Jiangsu HengRui Medicine Company Details 11.7.2 Jiangsu HengRui Medicine Business Overview 11.7.3 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Introduction 11.7.4 Jiangsu HengRui Medicine Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.7.5 Jiangsu HengRui Medicine Recent Development 11.8 Odonate Therapeutics 11.8.1 Odonate Therapeutics Company Details 11.8.2 Odonate Therapeutics Business Overview 11.8.3 Odonate Therapeutics HER2-Positive Breast Cancer Introduction 11.8.4 Odonate Therapeutics Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.8.5 Odonate Therapeutics Recent Development 11.9 Radius Pharmaceuticals 11.9.1 Radius Pharmaceuticals Company Details 11.9.2 Radius Pharmaceuticals Business Overview 11.9.3 Radius Pharmaceuticals HER2-Positive Breast Cancer Introduction 11.9.4 Radius Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.9.5 Radius Pharmaceuticals Recent Development 11.10 Immunomedics 11.10.1 Immunomedics Company Details 11.10.2 Immunomedics Business Overview 11.10.3 Immunomedics HER2-Positive Breast Cancer Introduction 11.10.4 Immunomedics Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.10.5 Immunomedics Recent Development 11.11 Syndax Pharmaceuticals 11.11.1 Syndax Pharmaceuticals Company Details 11.11.2 Syndax Pharmaceuticals Business Overview 11.11.3 Syndax Pharmaceuticals HER2-Positive Breast Cancer Introduction 11.11.4 Syndax Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.11.5 Syndax Pharmaceuticals Recent Development 11.12 Bayer 11.12.1 Bayer Company Details 11.12.2 Bayer Business Overview 11.12.3 Bayer HER2-Positive Breast Cancer Introduction 11.12.4 Bayer Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.12.5 Bayer Recent Development 11.13 Eagle Pharmaceuticals 11.13.1 Eagle Pharmaceuticals Company Details 11.13.2 Eagle Pharmaceuticals Business Overview 11.13.3 Eagle Pharmaceuticals HER2-Positive Breast Cancer Introduction 11.13.4 Eagle Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.13.5 Eagle Pharmaceuticals Recent Development 11.14 Merrimack Pharmaceuticals 11.14.1 Merrimack Pharmaceuticals Company Details 11.14.2 Merrimack Pharmaceuticals Business Overview 11.14.3 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Introduction 11.14.4 Merrimack Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.14.5 Merrimack Pharmaceuticals Recent Development 11.15 GlaxoSmithKline 11.15.1 GlaxoSmithKline Company Details 11.15.2 GlaxoSmithKline Business Overview 11.15.3 GlaxoSmithKline HER2-Positive Breast Cancer Introduction 11.15.4 GlaxoSmithKline Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.15.5 GlaxoSmithKline Recent Development 11.16 Millennium Pharmaceuticals 11.16.1 Millennium Pharmaceuticals Company Details 11.16.2 Millennium Pharmaceuticals Business Overview 11.16.3 Millennium Pharmaceuticals HER2-Positive Breast Cancer Introduction 11.16.4 Millennium Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) 11.16.5 Millennium Pharmaceuticals Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global HER2-Positive Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Grifola Frondosa Table 3. Key Players of Surgery Table 4. Key Players of Radiation and Chemotherapy Table 5. Key Players of Endocrine Therapy Table 6. Key Players of Molecular Targeted Therapy Table 7. Global HER2-Positive Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 8. Global HER2-Positive Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 9. Global HER2-Positive Breast Cancer Market Size by Regions (2016-2021) & (US$ Million) Table 10. Global HER2-Positive Breast Cancer Market Share by Regions (2016-2021) Table 11. Global HER2-Positive Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 12. Global HER2-Positive Breast Cancer Market Share by Regions (2022-2027) Table 13. HER2-Positive Breast Cancer Market Trends Table 14. HER2-Positive Breast Cancer Market Drivers Table 15. HER2-Positive Breast Cancer Market Challenges Table 16. HER2-Positive Breast Cancer Market Restraints Table 17. Global HER2-Positive Breast Cancer Revenue by Players (2016-2021) & (US$ Million) Table 18. Global HER2-Positive Breast Cancer Market Share by Players (2016-2021) Table 19. Global Top HER2-Positive Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-Positive Breast Cancer as of 2020) Table 20. Ranking of Global Top HER2-Positive Breast Cancer Companies by Revenue (US$ Million) in 2020 Table 21. Global 5 Largest Players Market Share by HER2-Positive Breast Cancer Revenue (CR5 and HHI) & (2016-2021) Table 22. Key Players Headquarters and Area Served Table 23. Key Players HER2-Positive Breast Cancer Product Solution and Service Table 24. Date of Enter into HER2-Positive Breast Cancer Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 27. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2016-2021) Table 28. Global HER2-Positive Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million) Table 29. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million) Table 30. Global HER2-Positive Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million) Table 31. Global HER2-Positive Breast Cancer Revenue Market Share by Application (2016-2021) Table 32. Global HER2-Positive Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million) Table 33. Global HER2-Positive Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million) Table 34. North America HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 35. North America HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 36. North America HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 37. North America HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 38. North America HER2-Positive Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 39. North America HER2-Positive Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 40. Europe HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 41. Europe HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 42. Europe HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 43. Europe HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 44. Europe HER2-Positive Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 45. Europe HER2-Positive Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 46. Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 47. Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 48. Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 49. Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 50. Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2016-2021) & (US$ Million) Table 51. Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2022-2027) & (US$ Million) Table 52. Latin America HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 53. Latin America HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 54. Latin America HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 55. Latin America HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 56. Latin America HER2-Positive Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 57. Latin America HER2-Positive Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 58. Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 59. Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 60. Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 61. Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 62. Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 63. Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 64. Pfizer (Pharmacia and Upjohn Company) Company Details Table 65. Pfizer (Pharmacia and Upjohn Company) Business Overview Table 66. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product Table 67. Pfizer (Pharmacia and Upjohn Company) Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 68. Pfizer (Pharmacia and Upjohn Company) Recent Development Table 69. Novartis Company Details Table 70. Novartis Business Overview Table 71. Novartis HER2-Positive Breast Cancer Product Table 72. Novartis Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 73. Novartis Recent Development Table 74. AstraZeneca Pharmaceuticals Company Details Table 75. AstraZeneca Pharmaceuticals Business Overview Table 76. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product Table 77. AstraZeneca Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 78. AstraZeneca Pharmaceuticals Recent Development Table 79. Eli Lilly Company Details Table 80. Eli Lilly Business Overview Table 81. Eli Lilly HER2-Positive Breast Cancer Product Table 82. Eli Lilly Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 83. Eli Lilly Recent Development Table 84. Roche Group Company Details Table 85. Roche Group Business Overview Table 86. Roche Group HER2-Positive Breast Cancer Product Table 87. Roche Group Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 88. Roche Group Recent Development Table 89. Merck Company Details Table 90. Merck Business Overview Table 91. Merck HER2-Positive Breast Cancer Product Table 92. Merck Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 93. Merck Recent Development Table 94. Jiangsu HengRui Medicine Company Details Table 95. Jiangsu HengRui Medicine Business Overview Table 96. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product Table 97. Jiangsu HengRui Medicine Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 98. Jiangsu HengRui Medicine Recent Development Table 99. Odonate Therapeutics Company Details Table 100. Odonate Therapeutics Business Overview Table 101. Odonate Therapeutics Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 102. Odonate Therapeutics Recent Development Table 103. Radius Pharmaceuticals Company Details Table 104. Radius Pharmaceuticals Business Overview Table 105. Radius Pharmaceuticals HER2-Positive Breast Cancer Product Table 106. Radius Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 107. Radius Pharmaceuticals Recent Development Table 108. Immunomedics Company Details Table 109. Immunomedics Business Overview Table 110. Immunomedics HER2-Positive Breast Cancer Product Table 111. Immunomedics Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 112. Immunomedics Recent Development Table 113. Syndax Pharmaceuticals Company Details Table 114. Syndax Pharmaceuticals Business Overview Table 115. Syndax Pharmaceuticals HER2-Positive Breast Cancer Product Table 116. Syndax Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 117. Syndax Pharmaceuticals Recent Development Table 118. Bayer Company Details Table 119. Bayer Business Overview Table 120. Bayer HER2-Positive Breast Cancer Product Table 121. Bayer Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 122. Bayer Recent Development Table 123. Eagle Pharmaceuticals Company Details Table 124. Eagle Pharmaceuticals Business Overview Table 125. Eagle Pharmaceuticals HER2-Positive Breast Cancer Product Table 126. Eagle Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 127. Eagle Pharmaceuticals Recent Development Table 128. Merrimack Pharmaceuticals Company Details Table 129. Merrimack Pharmaceuticals Business Overview Table 130. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product Table 131. Merrimack Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 132. Merrimack Pharmaceuticals Recent Development Table 133. GlaxoSmithKline Company Details Table 134. GlaxoSmithKline Business Overview Table 135. GlaxoSmithKline HER2-Positive Breast Cancer Product Table 136. GlaxoSmithKline Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 137. GlaxoSmithKline Recent Development Table 138. Millennium Pharmaceuticals Company Details Table 139. Millennium Pharmaceuticals Business Overview Table 140. Millennium Pharmaceuticals HER2-Positive Breast Cancer Product Table 141. Millennium Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million) Table 142. Millennium Pharmaceuticals Recent Development Table 143. Research Programs/Design for This Report Table 144. Key Data Information from Secondary Sources Table 145. Key Data Information from Primary Sources List of Figures Figure 1. Global HER2-Positive Breast Cancer Market Share by Type: 2020 VS 2027 Figure 2. Grifola Frondosa Features Figure 3. Surgery Features Figure 4. Radiation and Chemotherapy Features Figure 5. Endocrine Therapy Features Figure 6. Molecular Targeted Therapy Features Figure 7. Global HER2-Positive Breast Cancer Market Share by Application: 2020 VS 2027 Figure 8. Hospital Case Studies Figure 9. Specialist Clinic Case Studies Figure 10. Biotechnology and Pharmaceutical Companies Case Studies Figure 11. Research and Academic Institutions Case Studies Figure 12. Other Case Studies Figure 13. HER2-Positive Breast Cancer Report Years Considered Figure 14. Global HER2-Positive Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 15. Global HER2-Positive Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 16. Global HER2-Positive Breast Cancer Market Share by Regions: 2020 VS 2027 Figure 17. Global HER2-Positive Breast Cancer Market Share by Regions (2022-2027) Figure 18. Global HER2-Positive Breast Cancer Market Share by Players in 2020 Figure 19. Global Top HER2-Positive Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-Positive Breast Cancer as of 2020 Figure 20. The Top 10 and 5 Players Market Share by HER2-Positive Breast Cancer Revenue in 2020 Figure 21. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2016-2021) Figure 22. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2022-2027) Figure 23. North America HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. North America HER2-Positive Breast Cancer Market Share by Type (2016-2027) Figure 25. North America HER2-Positive Breast Cancer Market Share by Application (2016-2027) Figure 26. North America HER2-Positive Breast Cancer Market Share by Country (2016-2027) Figure 27. United States HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. Canada HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. Europe HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. Europe HER2-Positive Breast Cancer Market Share by Type (2016-2027) Figure 31. Europe HER2-Positive Breast Cancer Market Share by Application (2016-2027) Figure 32. Europe HER2-Positive Breast Cancer Market Share by Country (2016-2027) Figure 33. Germany HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. France HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. U.K. HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Italy HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Russia HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Nordic HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Asia-Pacific HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Asia-Pacific HER2-Positive Breast Cancer Market Share by Type (2016-2027) Figure 41. Asia-Pacific HER2-Positive Breast Cancer Market Share by Application (2016-2027) Figure 42. Asia-Pacific HER2-Positive Breast Cancer Market Share by Region (2016-2027) Figure 43. China HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Japan HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. South Korea HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Southeast Asia HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. India HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Australia HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Latin America HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Latin America HER2-Positive Breast Cancer Market Share by Type (2016-2027) Figure 51. Latin America HER2-Positive Breast Cancer Market Share by Application (2016-2027) Figure 52. Latin America HER2-Positive Breast Cancer Market Share by Country (2016-2027) Figure 53. Mexico HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Brazil HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Middle East & Africa HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Middle East & Africa HER2-Positive Breast Cancer Market Share by Type (2016-2027) Figure 57. Middle East & Africa HER2-Positive Breast Cancer Market Share by Application (2016-2027) Figure 58. Middle East & Africa HER2-Positive Breast Cancer Market Share by Country (2016-2027) Figure 59. Turkey HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. Saudi Arabia HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 61. UAE HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 62. Pfizer (Pharmacia and Upjohn Company) Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 63. Novartis Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 64. AstraZeneca Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 65. Eli Lilly Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 66. Roche Group Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 67. Merck Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 68. Jiangsu HengRui Medicine Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 69. Odonate Therapeutics Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 70. Radius Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 71. Immunomedics Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 72. Syndax Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 73. Bayer Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 74. Eagle Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 75. Merrimack Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 76. GlaxoSmithKline Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 77. Millennium Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021) Figure 78. Bottom-up and Top-down Approaches for This Report Figure 79. Data Triangulation Figure 80. Key Executives Interviewed

Pfizer (Pharmacia and Upjohn Company) Novartis AstraZeneca Pharmaceuticals Eli Lilly Roche Group Merck Jiangsu HengRui Medicine Odonate Therapeutics Radius Pharmaceuticals Immunomedics Syndax Pharmaceuticals Bayer Eagle Pharmaceuticals Merrimack Pharmaceuticals GlaxoSmithKline Millennium Pharmaceuticals